Cencora (NYSE:COR) Updates FY 2026 Earnings Guidance

Cencora (NYSE:COR) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 17.750-17.950 for the period, compared to the consensus EPS estimate of 17.850. The company issued revenue guidance of -.

Analyst Ratings Changes

A number of research analysts recently issued reports on COR shares. Wells Fargo & Company boosted their price objective on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their target price on shares of Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Evercore reiterated an “outperform” rating and issued a $350.00 price target on shares of Cencora in a research report on Thursday, August 6th. Finally, UBS Group increased their price objective on shares of Cencora from $412.00 to $430.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $374.25.

Cencora Stock Performance

NYSE COR opened at $313.86 on Friday. The firm has a market cap of $59.89 billion, a price-to-earnings ratio of 23.32, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The business has a 50-day moving average price of $298.98 and a 200-day moving average price of $313.24. Cencora has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The firm had revenue of $84.75 billion during the quarter, compared to analysts’ expectations of $84.31 billion. During the same quarter last year, the business posted $4.00 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. As a group, equities research analysts predict that Cencora will post 17.84 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is presently 17.83%.

Cencora announced that its board has initiated a stock repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Cencora

In related news, Director Lauren M. Tyler bought 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.38% of the company’s stock.

Institutional Trading of Cencora

Hedge funds have recently bought and sold shares of the stock. Compound Planning Inc. increased its holdings in shares of Cencora by 28.1% in the fourth quarter. Compound Planning Inc. now owns 1,505 shares of the company’s stock worth $508,000 after purchasing an additional 330 shares during the last quarter. Axxcess Wealth Management LLC boosted its stake in Cencora by 69.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 16,721 shares of the company’s stock valued at $5,648,000 after buying an additional 6,853 shares during the last quarter. Note Advisors LLC grew its holdings in Cencora by 9,906.0% during the 4th quarter. Note Advisors LLC now owns 73,244 shares of the company’s stock valued at $24,738,000 after buying an additional 72,512 shares in the last quarter. Strive Financial Group LLC bought a new stake in Cencora in the 4th quarter worth approximately $2,636,000. Finally, First Commonwealth Financial Corp PA raised its holdings in shares of Cencora by 5.0% during the 4th quarter. First Commonwealth Financial Corp PA now owns 3,425 shares of the company’s stock worth $1,157,000 after acquiring an additional 163 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.